Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions, announced that CEO Michael Halstead will take part in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, scheduled for September 14-16, 2026. The session, set for September 14 at 9 a.m. EDT, will be webcast live and later available for replay on the company's investor relations website. This engagement provides a platform for Helus to communicate its strategic direction and clinical milestones to the investment community, a critical step for a company operating in the high-risk, high-reward pharmaceutical sector.
The announcement arrives as Helus Pharma advances its lead candidate, HLP003, through Phase 3 clinical trials for major depressive disorder (MDD) as an adjunctive treatment, a program that has earned Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation underscores the potential for HLP003 to address a significant unmet need in MDD, where current therapies often provide inadequate relief. Additionally, the company is evaluating HLP004 in Phase 2 trials for generalized anxiety disorder, further broadening its pipeline. These programs are rooted in the company's proprietary NSA platform, which aims to activate serotonin pathways to promote neuroplasticity—a mechanism that could offer durable improvements over conventional treatments.
The conference participation is more than a routine investor relations exercise; it reflects the growing interest in psychedelic-inspired therapies and the need for novel approaches to mental health care. With depression and anxiety affecting hundreds of millions globally, the potential market for effective treatments is substantial. Helus Pharma's focus on synthetic molecules designed for targeted serotonin activation could distinguish it from competitors, especially as the industry navigates regulatory and safety challenges. The company's progress in late-stage trials, if successful, could first-in-class approvals and reshape treatment paradigms, offering new hope to patients who have not responded to existing options.
For investors, the conference presentation offers an opportunity to gauge the company's execution capabilities and the robustness of its clinical data. The live webcast and subsequent replay ensure broader access, aligning with the company's efforts to maintain transparency. Helus Pharma, operating under the commercial name Cybin Inc., has established a presence across Canada, the United States, the United Kingdom, and Ireland, and continues to expand its research portfolio of investigational NSAs. As the company approaches potential regulatory filings and data readouts, its visibility at top-tier investment events could influence market sentiment and partnerships.
The significance of this announcement lies in the timing: with mental health crises on the rise, the successful development of NSAs could address gaps in current treatment options. Helus Pharma's commitment to advancing HLP003 and HLP004 demonstrates a focused strategy toward bringing innovative therapies to market. The conference, known for attracting key industry players and investors, serves as a venue for Helus to articulate its value proposition, potentially catalyzing interest and support as it navigates the complex path to commercialization.
